New hope for hepatitis c: experimental combo targets hard-to-treat genotype 1
NCT ID NCT01753557
First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 20 times
Summary
This study tested a new drug called MP-424 combined with two standard hepatitis C medications (PEG-IFN and RBV) in 54 adults with genotype 1 hepatitis C who were either new to treatment or had relapsed after previous therapy. The main goal was to see if the virus could be cleared from the blood 24 weeks after treatment ended. People with severe liver damage, other infections, or certain mental health conditions were not included.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C(CHC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, 213-8587, Japan
Conditions
Explore the condition pages connected to this study.